Abstracts tagged "Spondyloarthropathies"

Abstract Number: 1035 • ACR Convergence 2022
Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
Philip J Mease¹, William Tillett², Sarah Ohrndorf³, Michelle Perate⁴, Mary Medysky⁵, Miriam Zimmermann⁶, May Shawi⁷, Emmanouil Rampakakis⁸, Paul Bird⁹, Alen Zabotti¹⁰, Atul Deodhar¹¹ and Dafna Gladman¹², ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Seattle, WA, ⁶Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹University of New South Wales, Sydney, Australia, ¹⁰Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ¹²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Evidence on the efficacy of advanced therapies for axial involvement in PsA (axPsA) is scarce, largely due to the lack of a widely accepted…
Abstract Number: 1768 • ACR Convergence 2022
Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
Sanjana Tarannum¹, Jessica Widdifield¹, C. Fangyun Wang², Sindhu R. Johnson³, Paula Rochon¹ and Lihi Eder⁴, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Delayed diagnosis of inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), is associated with joint damage and disability.…
Abstract Number: 0796 • ACR Convergence 2022
SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?
Carla Goncalves Schahin Saad¹, Matheus SR Silva², PERCIVAL SAMPAIO-BARROS¹, Julio Moraes³, Claudia G Schainberg², Celio Roberto goncalves¹, Andrea Shimabuco¹, Nadia Aikawa¹, Emily Figueiredo Neves Yuki¹, Sandra Gofinet Pasoto⁴, Leonard VK Kupa², Renato K Aoyama², Carlo Araujo¹, Clovis A. Silva⁵, ana Medeiros⁶ and Eloisa Silva Dutra de Oliveira Bonfa⁴, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, ³Faculdade de Medicina da Universidade de Sao Paulo, Jundiai, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil
Background/Purpose: Spondyloarthritis(SpA) patients are exposed to a variety of immunosuppressors capable of reduce humoral responses to vaccination. In context of the SARS-CoV-2 pandemic, assessment of…
Abstract Number: 1037 • ACR Convergence 2022
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies
Xenofon Baraliakos¹, Dafna Gladman², Soumya Chakravarty³, Cinty Gong⁴, May Shawi⁵, Emmanouil Rampakakis⁶, Kishimoto Mitsumasa⁷, Enrique R Soriano⁸ and Philip J Mease⁹, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only…
Abstract Number: 2108 • ACR Convergence 2022
Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA
Stefan Siebert¹, Georg Schett², Siba P. Raychaudhuri³, Monica Guma⁴, Warner Chen⁵, Sheng Gao⁵, Soumya Chakravarty⁶, May Shawi⁷ and Proton Rahman⁸, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Universitätsklinikum Erlangen, Erlangen, Germany, ³Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Memorial University, St. John's, NL, Canada
Background/Purpose: The IL-23p19 inhibitor guselkumab has shown robust efficacy vs placebo (PBO) in the phase 3 DISCOVER-1 and DISCOVER-2 studies of adults with active PsA,1,2…
Abstract Number: 0800 • ACR Convergence 2022
Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications
Alina Kifayat¹, amy Wasserman², Kirk Sperber¹, Deana Nes³, Paul Arnaboldi⁴ and Julia Ash⁵, ¹New York Medical College at Westchester Medical Center, Valhalla, NY, ²New York Medical College at Westchester Medical Center, Armonk, NY, ³Bergen Medical Associates, Ridgewood, NJ, ⁴New York Medical College, Valhalla, NY, ⁵New York Medical College at Westchester Medical Center, Dobbs Ferry, NY
Background/Purpose: In patients with rheumatic diseases herpes zoster (HZ) has been identified as one of the most common infections associated with immunosuppression. Shingrix is a…
Abstract Number: 1041 • ACR Convergence 2022
Tofacitinib in Refractory Uveitis – an Observational Study
Nikhil Gupta¹ and Deepankur Mahajan², ¹Centre for Arthritis and Rheumatological diseases in Delhi, New Delhi, India, ²Mahajan Eye Centre, New Delhi, India
Background/Purpose: To evaluate the effect of generic tofacitinib in refractory uveitis patients.Methods: It was a prospective observational study of 23 patients of refractory anterior uveitis.…
Abstract Number: 2109 • ACR Convergence 2022
Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Arthur Kavanaugh¹, Gordon Lam², Lai-shan Tam³, Natalie Shiff⁴, Youngja Lee⁵, Ana-Maria Bravo Perdomo⁶, May Shawi⁷, Elizabeth Hsia⁸, Emmanouil Rampakakis⁹ and Carlos Enrique Toro Gutiérrez¹⁰, ¹University of California San Diego, La Jolla, CA, ²Arthritis and Osteoporosis Consultants of the Carolinas; Clinical Affiliate, Atrium Health and the Wake Forest School of Medicine, Cornelius, NC, ³The Chinese University of Hong Kong, Hong Kong, China, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, ⁵Immunology Medical Affairs, Janssen Asia Pacific, Yongsan-gu, Seoul, Republic of Korea, ⁶Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Janssen Research and Development, LLC; University of Pennsylvania School of Medicine, Kennett Square, PA, ⁹McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ¹⁰Internal Medicine and Rheumatology, Reference Center for Osteoporosis, Rheumatology & Dermatology. Pontificia Javeriana University, Calí, Colombia
Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…
Abstract Number: 0854 • ACR Convergence 2022
Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study
Filipe Pinheiro¹, Mariana Leuzinger-Dias², Bruno Fernandes³, Diogo Fonseca⁴, Joana Vilaça⁵, Luís Figueira⁶ and Iva Brito⁷, ¹Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ²Ophtalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ³Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, ⁴Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, ⁵Paediatrics Department, Hospital de Braga, Braga, Portugal, ⁶Ophthalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ⁷Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal
Background/Purpose: Uveitis is a frequent complication of juvenile idiopathic arthritis (JIA) and juvenile spondyloarthritis (jSpA), and diagnosis is often challenging. The importance of uveitis relates…
Abstract Number: 1162 • ACR Convergence 2022
Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthritis After One Year of Biological Treatment
valeria Rios-Rodriguez¹, Morgan Essex², Judith Rademacher³, Murat Torgutalp⁴, Fabian Proft⁵, Ulrike Löber², Lajos Marko², Sofia Forslund² and Denis Poddubnyy⁵, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin, Berlin, Berlin, Germany, ⁵Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: There is little evidence about the effect of biological disease-modifying antirheumatic drugs (bDMARD) on gut dysbiosis in patients with axial SpA. Here we investigated…
Abstract Number: 2111 • ACR Convergence 2022
Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Dafna Gladman¹, Michael Starr², Roberto Ranza³, Ana-Maria Bravo Perdomo⁴, Marcie Strauss⁵, May Shawi⁶, Chenglong Han⁷, Emmanouil Rampakakis⁸, Andrew Ostor⁹ and Philip J Mease¹⁰, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Montreal General Hospital, Montréal, QC, Canada, ³Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, ⁵Medasource, Indianapolis, IN, ⁶Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁷Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹Cabrini Medical Centre, Monash University & Emeritus Research, Melbourne, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA…
Abstract Number: 0865 • ACR Convergence 2022
Opioid Use in Youth with Inflammatory Bowel Disease (IBD)-related Arthritis
Atiye Bilgic Dagci¹, Joyce Chang², Rui Xiao³, Andrew Grossman⁴ and Pamela Weiss⁵, ¹Children's Hospital of Philadelphia, Bala Cynwyd, PA, ²Boston Children's Hospital, Boston, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Philadelphia, ⁵Children's Hospital of Philadelphia, Glen Mills, PA
Background/Purpose: Opioid use is common among youth with IBD and associated with increased health care utilization and opioid dependence. Arthritis affects up to 20% of…
Abstract Number: 1164 • ACR Convergence 2022
Expanded CD8+ T Cell Clones from HLA-B*27-positive Patients with Spondyloarthritis Show Signs of Antigen-experience
Judith Rademacher¹, Katharina Deschler², Sonja Lacher², Alina Huth², Markus Utzt², Stefan Krebs², Helmut Blum², Eduardo Beltrán², Klaus Dornmair² and Denis Poddubnyy³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Laboratory for Functional Genome Analysis (LAFUGA), Gene Center of the LMU Munich, Munich, Germany, ³Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Spondyloarthritis (SpA) is strongly associated with HLA-B27. The arthritogenic antigen hypothesis assumes the existence of specific peptides presented by risk-conferring HLA-B27 alleles to antigen-specific…
Abstract Number: 2112 • ACR Convergence 2022
Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Christopher Ritchlin¹, Philip J Mease², Wolf-Henning Boehncke³, John Tesser⁴, Soumya Chakravarty⁵, Emmanouil Rampakakis⁶, May Shawi⁷, Elena Schiopu⁸, Joseph Merola⁹, Iain B McInnes¹⁰ and Atul Deodhar¹¹, ¹Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Deptartment of Dermatology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland, ⁴Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁵Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ⁹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁰Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3…
Abstract Number: 0868 • ACR Convergence 2022
Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome
Joy Um¹, Douglas Einstadter², Myung-Yong Um³ and Maria Antonelli¹, ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Center for Health Care Research and Policy, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ³Department of Social Welfare, Sungkyunkwan University, Seoul, Republic of Korea
Background/Purpose: Spondyloarthritis (SpA) consists of clinically and genetically related but phenotypically distinct disorders, including ankylosing spondylitis, enteropathic arthritis, psoriatic arthritis, reactive arthritis, and enthesitis-related arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].